Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 2, 2008, Pages 268-276

  Emonts, M ^a   De Bruijne, E L E ^a,c   Guimaraes A H C ^b   Declerck, P J ^d   Leebeek, F W G ^b   De Maat, M P M ^b   Rijken, D C ^b   Hazelzet, J A ^a   Gils, A ^d  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RED CROSS HOSPITAL   (Netherlands)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Coagulation; Fibrinolysis; Neisseria meningitidis; Pathogenesis; Pediatric

Indexed keywords

ADENINE; ALANINE; BIOLOGICAL MARKER; GUANINE; ISOLEUCINE; PEPTIDE; THREONINE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; CONVALESCENCE; CORRELATION ANALYSIS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOSPITAL ADMISSION; HUMAN; INFANT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MORTALITY; NEISSERIA MENINGITIDIS; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; SEPTIC SHOCK; SURVIVAL;

EID: 38549157626     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.02841.x     Document Type: Article

References (38)

1. Booy R, Habibi P, Nadel S, de Munter C, Britto J, Morrison A, Levin M. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001; 85: 386-90.
2. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
3. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
4. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
5. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
6. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ Jr, Fay WP, Morser J. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
7. Renckens R, Roelofs JJ, ter Horst SA, van't Veer C, Havik SR, Florquin S, Wagenaar GT, Meijers JC, van der Poll T. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005; 175: 6764-71.
8. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-67.
9. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46: 131-4.
10. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118: 205-12.
11. Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001; 104: 1-6.
12. Knoefler R, Ludwig K, Kostka H, Kuhlisch E, Siegert G, Suttorp M. The impact of single nucleotide polymorphisms of the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI antigen levels in healthy children and pediatric oncology patients. Semin Thromb Hemost 2003; 29: 575-83.
13. Leurs J, Hendriks D. Carboxypeptidase U (TAFIa): A metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005; 94: 471-87.
14. de Kleijn ED, de Groot R, Hack CE, PG HM, Engl W, Moritz B, Joosten KF, Hazelzet JA. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003; 31: 1839-47.
15. van der Kaay DC, de Kleijn ED, de Rijke YB, Hop WC, De Groot R, Hazelzet JA. Procalcitonin as a prognostic marker in meningococcal disease. Intensive Care Med 2002; 28: 1606-12.
16. Vermont CL, den Brinker M, Kakeci N, de Kleijn ED, de Rijke YB, Joosten KF, de Groot R, Hazelzet JA. Serum lipids and disease severity in children with severe meningococcal sepsis. Crit Care Med 2005; 33: 1610-5.
17. de Groof F, Joosten KF, Janssen JA, de Kleijn ED, Hazelzet JA, Hop WC, Uitterlinden P, van Doorn J, Hokken-Koelega AC. Acute stress response in children with meningococcal sepsis: Important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors. J Clin Endocrinol Metab 2002; 87: 3118-24.
18. den Brinker M, Joosten KF, Liem O, de Jong FH, Hop WC, Hazelzet JA, van Dijk M, Hokken-Koelega AC. Adrenal insufficiency in meningococcal sepsis: Bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab 2005; 90: 5110-7.
19. Derkx B, Wittes J, McCloskey R. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis 1999; 28: 770-7.
20. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6: 2-8.
21. Kornelisse RF, Hazelzet JA, Hop WC, Spanjaard L, Suur MH, van der Voort E, de Groot R. Meningococcal septic shock in children: Clinical and laboratory features, outcome, and development of a prognostic score. Clin Infect Dis 1997; 25: 640-6.
22. Pollack MM, Ruttimann UE, Getson PR. Pediatric risk of mortality (PRISM) score. Crit Care Med 1988; 16: 1110-6.
23. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-30.
24. van der Ende A, Schuurman IG, Hopman CT, Fijen CA, Dankert J. Comparison of commercial diagnostic tests for identification of serogroup antigens of Neisseria meningitidis. J Clin Microbiol 1995; 33: 3326-7.
25. Ceresa E, Brouwers E, Peeters M, Jern C, Declerck PJ, Gils A. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol 2006; 26: 423-8.
26. Vermont CL, Hazelzet JA, de Kleijn ED, van den Dobbelsteen GP, Groot RD. CC and CXC chemokine levels in children with meningococcal sepsis accurately predict mortality and disease severity. Crit Care 2006; 10: R33.
27. Bland JM, Altman DG. Transformations, means, and confidence intervals. BMJ 1996; 312: 1079.
28. Hazelzet JA. Diagnosing meningococcemia as a cause of sepsis. Pediatr Crit Care Med 2005; 6: S50-4.
29. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-801.
30. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: Biology and regulation. Cell Mol Life Sci 1999; 56: 104-32.
31. de Kleijn ED, Hazelzet JA, Kornelisse RF, de Groot R. Pathophysiology of meningococcal sepsis in children. Eur J Pediatr 1998; 157: 869-80.
32. Hazelzet JA, de Groot R, van Mierlo G, Joosten KF, van der Voort E, Eerenberg A, Suur MH, Hop WC, Hack CE. Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect Immun 1998; 66: 5350-6.
33. Maat M, Buysse CM, Emonts M, Spanjaard L, Joosten KF, de Groot R, Hazelzet JA. Improved survival of children with sepsis and purpura: effects of age, gender, and era. Crit Care 2007; 11: R112.
34. Chen CC, Lee KD, Gau JP, Yu YB, You JY, Lee SC, Hsu HC, Chau WK, Ho CH. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation. Ann Hematol 2005; 84: 675-80.
35. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 1021-30.
36. Guimaraes AH, Bertina RM, Rijken DC. A new functional assay of thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2005; 3: 1284-92.
37. Kremer Hovinga JA, Franco RF, Zago MA, Ten Cate H, Westendorp RG, Reitsma PH. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. J Thromb Haemost 2004; 2: 54-7.
38. Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999; 25: 556-66.